4.27
Schlusskurs vom Vortag:
$4.41
Offen:
$4.2
24-Stunden-Volumen:
63,448
Relative Volume:
1.05
Marktkapitalisierung:
$54.87M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-11.73M
KGV:
-3.0884
EPS:
-1.3826
Netto-Cashflow:
$-10.37M
1W Leistung:
+4.40%
1M Leistung:
+17.96%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Branche
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Vergleichen Sie MDCX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MDCX
Medicus Pharma Ltd
|
4.27 | 54.87M | 0 | -11.73M | -10.37M | -1.3826 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions - Proactive Investors
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
Medicus Pharma signs letter of intent to buy British biotech company - The Business Journals
Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma to acquire Antev in strategic biotech deal By Investing.com - Investing.com South Africa
Medicus Pharma to acquire Antev in strategic biotech deal - Investing.com Australia
Small cap wrap: Medicus Pharma, Arizona Gold & Silver, Plug Power... - Proactive Investors
Market movers: Nvidia, Plug Power, Medicus Pharma... - Proactive financial news
Medicus Pharma Ltd To Acquire Antev Ltd. For $75 Million In A Share Exchange Transaction - marketscreener.com
Medicus Pharma to Acquire Antev Ltd. in $75 Million Deal - TipRanks
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction - Malay Mail
Medicus Pharma to acquire Antev, expanding pipeline with potentially first-in-class prostate treatment - Proactive financial news
Medicus Pharma Ltd’s Promising Clinical Developments and Strategic Expansion Drive Buy Rating - TipRanks
Medicus Pharma (NASDAQ:MDCX) Given Buy Rating at D. Boral Capital - Defense World
Medicus Pharma expands patient enrollment for skin cancer study By Investing.com - Investing.com Canada
Small cap wrap: Medicus Pharma, HIVE Digital Technologies, Spanish Mountain Gold... - Proactive Investors
Medicus Pharma expands basal cell carcinoma study after encouraging early data - Proactive financial news
Medicus Pharma Expands Phase 2 Study for Basal Cell Carcinoma Treatment - TipRanks
Medicus Pharma expands patient enrollment for skin cancer study - Investing.com
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC) - Newsfile
Medicus Pharma (CVE:MDC) Raised to Strong-Buy at D Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Raised to Strong-Buy at D Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Coverage Initiated by Analysts at D. Boral Capital - Defense World
Medicus Pharma initiated with a Buy at D. Boral Capital - TipRanks
Medicus Pharma Ltd. - FinancialContent
This Millrose Properties Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
FY2025 EPS Estimate for Medicus Pharma Lifted by Analyst - Defense World
Brokers Set Expectations for Medicus Pharma Q1 Earnings - The AM Reporter
Research Analysts Issue Forecasts for Medicus Pharma Q1 Earnings - Defense World
Research Analysts Set Expectations for Medicus Pharma Q1 Earnings - Defense World
Medicus Pharma secures $15 million funding option - MSN
Will Medicus' D-MNA Prove To Be A Non-Invasive, Effective Alternative To Mohs Surgery For BCC? - RTTNews
Medicus Pharma Ltd. SEC 10-K Report - TradingView
Medicus Pharma Ltd. (MDCX) reports earnings - Quartz
Healthcare Disruptors: AI, Telehealth and Cost Savings - Value The Markets
ValueTheMarkets Insights: While Big Pharma Stalls, One Small-Cap Breaks Out - WRAL.com
ValueTheMarkets Insights: Healthcare Climbs as Tech Stumbles in 2025 Shift - WRAL.com
While Big Pharma Stalls, One Small-Cap Breaks Out - TipRanks
Healthcare Climbs as Tech Stumbles in 2025 Shift - Value the Markets
Medicus Pharma cancels shareholder meeting notice By Investing.com - Investing.com Australia
Medicus Pharma cancels shareholder meeting notice - Investing.com
Pinpointing Hidden Stock Winners in a Volatile Market - Value The Markets
3 US Healthcare Stocks That Might Be Undervalued 2025 - Value The Markets
Medicus Pharma Share Price: MDCX Stock Closed Up 15.35%! - Value The Markets
Medicus Pharma announces annual meeting date - Investing.com
Medicus Pharma announces annual meeting date By Investing.com - Investing.com Australia
Advancing Oncology: Innovations in Treatment and Detection - Value The Markets
See Why Some Investors Are Watching This Biotech Company - Value The Markets
Biotech Stock Tapping $7B+ Skin Cancer Market Opportunity - Value The Markets
The Biotech Stocks Tackling the World’s Most Common Cancer - Value The Markets
Medicus Pharma - The Pharma Letter
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):